These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Long-Term Outcomes of Salvage Stereotactic Ablative Radiotherapy for Isolated Lung Recurrence of Non-Small Cell Lung Cancer: A Phase II Clinical Trial. Sun B; Brooks ED; Komaki R; Liao Z; Jeter M; McAleer M; Balter PA; Welsh JD; O'Reilly M; Gomez D; Hahn SM; Sepesi B; Rice DC; Heymach JV; Chang JY J Thorac Oncol; 2017 Jun; 12(6):983-992. PubMed ID: 28259750 [TBL] [Abstract][Full Text] [Related]
8. Association of Long-term Outcomes and Survival With Multidisciplinary Salvage Treatment for Local and Regional Recurrence After Stereotactic Ablative Radiotherapy for Early-Stage Lung Cancer. Brooks ED; Sun B; Feng L; Verma V; Zhao L; Gomez DR; Liao Z; Jeter M; O'Reilly M; Welsh JW; Nguyen QN; Erasmus JJ; Eapen G; Ahrar K; Antonoff MB; Hahn SM; Heymach JV; Rice DC; Chang JY JAMA Netw Open; 2018 Aug; 1(4):e181390. PubMed ID: 30646121 [TBL] [Abstract][Full Text] [Related]
9. Individualized Stereotactic Ablative Radiotherapy for Lung Tumors: The iSABR Phase 2 Nonrandomized Controlled Trial. Gensheimer MF; Gee H; Shirato H; Taguchi H; Snyder JM; Chin AL; Vitzthum LK; Maxim PG; Wakelee HA; Neal J; Das M; Chang DT; Kidd E; Hancock SL; Shultz DB; Horst KC; Le QT; Wong S; Brown E; Nguyen N; Liang R; Loo BW; Diehn M JAMA Oncol; 2023 Nov; 9(11):1525-1534. PubMed ID: 37707820 [TBL] [Abstract][Full Text] [Related]
10. Stereotactic Body Radiation Therapy for Operable Early-Stage Lung Cancer: Findings From the NRG Oncology RTOG 0618 Trial. Timmerman RD; Paulus R; Pass HI; Gore EM; Edelman MJ; Galvin J; Straube WL; Nedzi LA; McGarry RC; Robinson CG; Schiff PB; Chang G; Loo BW; Bradley JD; Choy H JAMA Oncol; 2018 Sep; 4(9):1263-1266. PubMed ID: 29852037 [TBL] [Abstract][Full Text] [Related]
11. Accelerated Hypofractionated Chemoradiation Followed by Stereotactic Ablative Radiotherapy Boost for Locally Advanced, Unresectable Non-Small Cell Lung Cancer: A Nonrandomized Controlled Trial. Wu TC; Luterstein E; Neilsen BK; Goldman JW; Garon EB; Lee JM; Felix C; Cao M; Tenn SE; Low DA; Kupelian PA; Steinberg ML; Lee P JAMA Oncol; 2024 Mar; 10(3):352-359. PubMed ID: 38206614 [TBL] [Abstract][Full Text] [Related]
12. Stereotactic Ablative Radiation Therapy is Highly Safe and Effective for Elderly Patients With Early-stage Non-Small Cell Lung Cancer. Brooks ED; Sun B; Zhao L; Komaki R; Liao Z; Jeter M; Welsh JW; O'Reilly MS; Gomez DR; Hahn SM; Heymach JV; Rice DC; Chang JY Int J Radiat Oncol Biol Phys; 2017 Jul; 98(4):900-907. PubMed ID: 28258887 [TBL] [Abstract][Full Text] [Related]
13. Stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a non-randomised phase 2 trial. Siva S; Bressel M; Sidhom M; Sridharan S; Vanneste BGL; Davey R; Montgomery R; Ruben J; Foroudi F; Higgs B; Lin C; Raman A; Hardcastle N; Hofman MS; De Abreu Lourenco R; Shaw M; Mancuso P; Moon D; Wong LM; Lawrentschuk N; Wood S; Brook NR; Kron T; Martin J; Pryor D; Lancet Oncol; 2024 Mar; 25(3):308-316. PubMed ID: 38423047 [TBL] [Abstract][Full Text] [Related]
14. 7-year follow-up after stereotactic ablative radiotherapy for patients with stage I non-small cell lung cancer: Results of a phase 2 clinical trial. Sun B; Brooks ED; Komaki RU; Liao Z; Jeter MD; McAleer MF; Allen PK; Balter PA; Welsh JD; O'Reilly MS; Gomez D; Hahn SM; Roth JA; Mehran RJ; Heymach JV; Chang JY Cancer; 2017 Aug; 123(16):3031-3039. PubMed ID: 28346656 [TBL] [Abstract][Full Text] [Related]
15. Short report: interim safety results for a phase II trial measuring the integration of stereotactic ablative radiotherapy (SABR) plus surgery for early stage non-small cell lung cancer (MISSILE-NSCLC). Palma DA; Nguyen TK; Kwan K; Gaede S; Landis M; Malthaner R; Fortin D; Louie AV; Frechette E; Rodrigues GB; Yaremko B; Yu E; Dar AR; Lee TY; Gratton A; Warner A; Ward A; Inculet R Radiat Oncol; 2017 Jan; 12(1):30. PubMed ID: 28129789 [TBL] [Abstract][Full Text] [Related]
16. Outcomes of stereotactic ablative radiotherapy in patients with potentially operable stage I non-small cell lung cancer. Lagerwaard FJ; Verstegen NE; Haasbeek CJ; Slotman BJ; Paul MA; Smit EF; Senan S Int J Radiat Oncol Biol Phys; 2012 May; 83(1):348-53. PubMed ID: 22104360 [TBL] [Abstract][Full Text] [Related]
17. Stereotactic Ablative Radiation Therapy for Large (≥5 cm) Non-small Cell Lung Carcinoma. McDermott RL; Mihai A; Dunne M; Keys M; O'Sullivan S; Thirion P; ElBeltagi N; Armstrong JG Clin Oncol (R Coll Radiol); 2021 May; 33(5):292-299. PubMed ID: 33309479 [TBL] [Abstract][Full Text] [Related]
18. Consolidative stereotactic ablative radiotherapy (SABR) to intrapulmonary lesions is associated with prolonged progression-free survival and overall survival in oligometastatic NSCLC patients: A prospective phase 2 study. Blake-Cerda M; Lozano-Ruíz F; Maldonado-Magos F; de la Mata-Moya D; Díaz-García D; Lara-Mejía L; Zatarain-Barrón ZL; Cuevas-Góngora MF; Barron-Barron F; Corona-Cruz JF; Cabrera-Miranda L; Arroyo-Hernández M; Gerson R; Arrieta O Lung Cancer; 2021 Feb; 152():119-126. PubMed ID: 33385737 [TBL] [Abstract][Full Text] [Related]
19. Survival and quality of life after stereotactic or 3D-conformal radiotherapy for inoperable early-stage lung cancer. Widder J; Postmus D; Ubbels JF; Wiegman EM; Langendijk JA Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e291-7. PubMed ID: 21640503 [TBL] [Abstract][Full Text] [Related]
20. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Chang JY; Senan S; Paul MA; Mehran RJ; Louie AV; Balter P; Groen HJ; McRae SE; Widder J; Feng L; van den Borne BE; Munsell MF; Hurkmans C; Berry DA; van Werkhoven E; Kresl JJ; Dingemans AM; Dawood O; Haasbeek CJ; Carpenter LS; De Jaeger K; Komaki R; Slotman BJ; Smit EF; Roth JA Lancet Oncol; 2015 Jun; 16(6):630-7. PubMed ID: 25981812 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]